23rd World Congress of Dermatology: Vancouver, Canada, June 8-13, 2015.

Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G.B. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, Christopher E.M. Griffiths, Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Journal of The American Academy of Dermatology. ,vol. 73, pp. 37- 49 ,(2015) , 10.1016/J.JAAD.2015.03.049

Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher EM Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen-Fang Tsai, Norman Wasel, Stephen Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, Charis Papavassilis, None, Secukinumab in plaque psoriasis--results of two phase 3 trials. The New England Journal of Medicine. ,vol. 371, pp. 326- 338 ,(2014) , 10.1056/NEJMOA1314258

R.G. Langley, M. Lebwohl, G.G. Krueger, P.O. Szapary, Y. Wasfi, D. Chan, M.C. Hsu, Y. You, Y. Poulin, N. Korman, J.C. Prinz, K. Reich, , Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. British Journal of Dermatology. ,vol. 172, pp. 1371- 1383 ,(2015) , 10.1111/BJD.13469

Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Celine Bouchard, Constance Mao, Jesper Mehlsen, Edson D Moreira Jr, Yuen Ngan, Lone Kjeld Petersen, Eduardo Lazcano-Ponce, Punnee Pitisuttithum, Jaime Alberto Restrepo, Gavin Stuart, Linn Woelber, Yuh Cheng Yang, Jack Cuzick, Suzanne M Garland, Warner Huh, Susanne K Kjaer, Oliver M Bautista, Ivan SF Chan, Joshua Chen, Richard Gesser, Erin Moeller, Michael Ritter, Scott Vuocolo, Alain Luxembourg, None, A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women The New England Journal of Medicine. ,vol. 372, pp. 711- 723 ,(2015) , 10.1056/NEJMOA1405044

K Papp, D Thaçi, K Reich, E Riedl, RG Langley, JG Krueger, AB Gottlieb, H Nakagawa, EP Bowman, A Mehta, Q Li, Y Zhou, R Shames, None, Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial British Journal of Dermatology. ,vol. 173, pp. 930- 939 ,(2015) , 10.1111/BJD.13932

Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis, SCULPTURE Study Group, Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) Journal of The American Academy of Dermatology. ,vol. 73, pp. 27- 36 ,(2015) , 10.1016/J.JAAD.2015.04.011

Hervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, Joo-Heung Lee, Vladimir Yakusevich, Sergio Chimenti, Jocelyne Papacharalambous, James Proulx, Pankaj Gupta, Huaming Tan, Margaret Tawadrous, Hernan Valdez, Robert Wolk, Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial The Lancet. ,vol. 386, pp. 552- 561 ,(2015) , 10.1016/S0140-6736(14)62113-9

Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest, Susan Ball, Daniel K Braun, Olawale O Osuntokun, Michael P Heffernan, Brian J Nickoloff, Kim Papp, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials The Lancet. ,vol. 386, pp. 541- 551 ,(2015) , 10.1016/S0140-6736(15)60125-8